Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 94

1.

Patient outcomes and amotosalen/UVA-treated platelet utilization in massively transfused patients.

Nussbaumer W, Amato M, Schennach H, Astl M, Chen CY, Lin JS, Corash L, Benjamin RJ.

Vox Sang. 2017 Feb 15. doi: 10.1111/vox.12489. [Epub ahead of print]

PMID:
28198023
2.

Plasma treated with amotosalen and ultraviolet A light retains activity for hemostasis after 5 days post-thaw storage at 1 to 6o C.

Erickson A, Waldhaus K, David T, Huang N, Rico S, Corash L, Mufti N, Benjamin RJ.

Transfusion. 2017 Feb 1. doi: 10.1111/trf.13973. [Epub ahead of print]

PMID:
28150310
3.

Zika virus in the blood supply.

Benjamin RJ.

Blood. 2017 Jan 12;129(2):144-145. doi: 10.1182/blood-2016-12-751925. No abstract available.

PMID:
28082294
4.

Impact of platelet pathogen inactivation on blood component utilization and patient safety in a large Austrian Regional Medical Centre.

Amato M, Schennach H, Astl M, Chen CY, Lin JS, Benjamin RJ, Nussbaumer W.

Vox Sang. 2017 Jan;112(1):47-55. doi: 10.1111/vox.12456. Epub 2016 Dec 21.

PMID:
28001297
5.

Investigation of bacterial inactivation in apheresis platelets with 24 or 30 hours between inoculation and inactivation.

Wagner SJ, Benjamin RJ, Hapip CA, Kaelber NS, Turgeon AM, Skripchenko A, Stassinopoulos A.

Vox Sang. 2016 Oct;111(3):226-234. doi: 10.1111/vox.12410. Epub 2016 May 17.

PMID:
27185478
6.

Amotosalen and ultraviolet-A treated platelets and plasma are safe and efficacious in active hemorrhage.

Benjamin RJ, Carter KL, Corash L.

Transfusion. 2016 Oct;56(10):2649-2650. doi: 10.1111/trf.13786. No abstract available.

PMID:
27739155
7.
8.

Transfusion-related sepsis: a silent epidemic.

Benjamin RJ.

Blood. 2016 Jan 28;127(4):380-1. doi: 10.1182/blood-2015-12-685198.

9.

Bacterial pathogen reduction requires validation under conditions of intended use.

Benjamin RJ, Wagner SJ.

Transfusion. 2015 Sep;55(9):2060-3. doi: 10.1111/trf.13232. No abstract available.

PMID:
26372914
10.

The Safety of the Blood Supply--Time to Raise the Bar.

Snyder EL, Stramer SL, Benjamin RJ.

N Engl J Med. 2015 Aug 27;373(9):882. doi: 10.1056/NEJMc1507761. No abstract available.

11.

The safety of the blood supply--time to raise the bar.

Snyder EL, Stramer SL, Benjamin RJ.

N Engl J Med. 2015 May 14;372(20):1882-5. doi: 10.1056/NEJMp1500154. Epub 2015 Apr 22. No abstract available.

PMID:
25902384
12.

A clinical governance framework for blood services.

Williamson LM, Benjamin RJ, Devine DV, Katz LM, Pink J; Alliance of Blood Operators Medical Directors Group..

Vox Sang. 2015 May;108(4):378-86. doi: 10.1111/vox.12228. Epub 2015 Feb 17.

PMID:
25688854
13.

The international experience of bacterial screen testing of platelet components with an automated microbial detection system: a need for consensus testing and reporting guidelines.

Benjamin RJ, McDonald CP; ISBT Transfusion Transmitted Infectious Disease Bacterial Workgroup..

Transfus Med Rev. 2014 Apr;28(2):61-71. doi: 10.1016/j.tmrv.2014.01.001. Epub 2014 Feb 5. Review.

PMID:
24636779
14.

The impact of platelet additive solution apheresis platelets on allergic transfusion reactions and corrected count increment (CME).

Tobian AA, Fuller AK, Uglik K, Tisch DJ, Borge PD, Benjamin RJ, Ness PM, King KE.

Transfusion. 2014 Jun;54(6):1523-9; quiz 1522. doi: 10.1111/trf.12498. Epub 2013 Nov 19.

15.

Bacterial culture of apheresis platelets: a mathematical model of the residual rate of contamination based on unconfirmed positive results.

Benjamin RJ, Dy B, Perez J, Eder AF, Wagner SJ.

Vox Sang. 2014 Jan;106(1):23-30. doi: 10.1111/vox.12065. Epub 2013 Jul 2.

PMID:
23815166
16.

Clostridium perfringens in apheresis platelets: an unusual contaminant underscores the importance of clinical vigilance for septic transfusion reactions (CME).

Eder AF, Meena-Leist CE, Hapip CA, Dy BA, Benjamin RJ, Wagner SJ.

Transfusion. 2014 Mar;54(3 Pt 2):857-62; quiz 856. doi: 10.1111/trf.12282. Epub 2013 Jun 17.

PMID:
23772803
17.

The residual risk of transfusion-related acute lung injury at the American Red Cross (2008-2011): limitations of a predominantly male-donor plasma mitigation strategy.

Eder AF, Dy BA, Perez JM, Rambaud M, Benjamin RJ.

Transfusion. 2013 Jul;53(7):1442-9. doi: 10.1111/j.1537-2995.2012.03935.x. Epub 2012 Nov 1.

PMID:
23113676
18.

The effect of various platelet dosing strategies on transfusion costs.

Benjamin RJ.

Transfusion. 2012 Sep;52(9):1852-4. doi: 10.1111/j.1537-2995.2012.03731.x. Review. No abstract available.

PMID:
22946970
19.

The REDS-II Donor Iron Status Evaluation (RISE) study: conclusions should not exceed the limitations of the data.

Benjamin RJ.

Transfusion. 2012 Jun;52(6):1382-3; author reply 1383-5. doi: 10.1111/j.1537-2995.2012.03653.x. No abstract available.

PMID:
22686535
20.

Plasma components: properties, differences, and uses.

Benjamin RJ, McLaughlin LS.

Transfusion. 2012 May;52 Suppl 1:9S-19S. doi: 10.1111/j.1537-2995.2012.03622.x. Review.

PMID:
22578375

Supplemental Content

Loading ...
Support Center